Detoxified anthrax used to deliver cancer drugs within cells
MIT scientists have employed a harmless version of the anthrax causing bacteria for drug delivery purposes, using it to insert drugs known as antibody mimics inside cells in the fight against cancer.
CDC takes steps to improve lab safety after anthrax, flu scares
In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.
Vaccine prevents anthrax infection in preclinical tests
Biodefense company Soligenix revealed new data showing that a combination of its vaccines RiVax and VeloThrax induced protective immunity to both ricin toxin and anthrax toxin exposure in an animal study.
PharmAthene's anthrax vaccine candidate, SparVax, works at least as well as currently licensed BioThrax from Emergent BioSolutions--at least, according to a study in New Zealand white rabbits.
Blessed by Gates, crowdfunding site funnels cash for high-risk R&D
A new crowdfunding platform site called Microryza has started funneling cash to dozens of high-risk scientific research programs, including a number of drug development efforts that would otherwise never see the light of day.
FDA green-lights new anti-anthrax, rare disease drugs from GlaxoSmithKline and Novartis
The FDA is wrapping up business before the end of the year and making a flurry of approvals. The agency OK'd three new drugs Friday, with all of the green-lighted therapies sanctioned for combating relatively rare ailments and securing orphan drug status.
Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.
The U.S. government doled out a contract worth £4 million ($6.4 million) to the U.K.'s Health Protection Agency to develop a next-generation anthrax vaccine. The project will be valued at £14 million ($22.6 million) if all milestones are met.
Scientists from the U.K.'s Cardiff University are leading a NATO project to develop an anthrax vaccine.
NJ biotech wins $14.5M from U.S. gov't to study drug against anthrax
Uncle Sam has ponied up another $14.5 million in funding to advance Elusys Therapeutics' experimental drug for treating patients after anthrax attacks, according to the company. And the Pine Brook, NJ-based biopharma group is working on a plan for late-stage development of the antibody drug, ETI-204 or Anthim.